Observational Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Nov 28, 2024; 30(44): 4725-4737
Published online Nov 28, 2024. doi: 10.3748/wjg.v30.i44.4725
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of patient enrollment and follow-up. Peg-IFN-α: Peginterferon alpha; HCV: Hepatitis C virus.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Dynamic changes in hepatitis B surface antibody levels in the HBsAg seroconversion and non-seroconversion groups during 48 weeks of follow-up. aP < 0.001. HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 The baseline. A: Hepatitis B surface antigen seroconversion rate; B: Hepatitis B surface antibody level in the different consolidation therapy groups. bP < 0.01. HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Kaplan-Meier curves of the cumulative hepatitis B surface antigen recurrence rate. A: In the per-protocol; B: Intention-to-treat analyses. HBsAg: Hepatitis B surface antigen.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 The Kaplan-Meier curves. A: The Kaplan-Meier curves of the cumulative hepatitis B surface antigen (HBsAg) recurrence rate between the groups with different consolidation treatment times; B: The Kaplan-Meier curves of the cumulative HBsAg recurrence rate between the HBsAg seroconversion and non-seroconversion groups; C: The Kaplan-Meier curves of the cumulative HBsAg recurrence rate between the groups with and without hepatitis B surface antibody disappearance during follow-up. HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibody.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 During follow-up after the cessation of peginterferon alpha treatment. A: The hepatitis B surface antigen recurrence rate in the hepatitis B surface antibody (HBsAb) < 35.3 mIU/mL and HBsAb ≥ 35.3 mIU/mL groups at the cessation of peginterferon alpha (peg-IFN-α) treatment. bP < 0.01; B: The dynamics of median alanine aminotransferase and aspartate transaminase levels during follow-up after the cessation of peg-IFN-α treatment. HBsAb: Hepatitis B surface antibody; HBsAg: Hepatitis B surface antigen; ALT: Alanine aminotransferase; AST: Aspartate transaminase.